Build A Bear Workshop Inc vs Sanofi SA — how do they compare? Build A Bear Workshop Inc trades at $36.88 (market cap $467.15M), while Sanofi SA trades at $43.52 (market cap $104.57B). The key difference: Sanofi SA is far larger — about 223.8× Build A Bear Workshop Inc's market cap, and Sanofi SA pays the higher dividend (5.56%). Which is the better fit depends on your goals.
| BBW | SNY | |
|---|---|---|
Market Cap | $467.15M | $104.57B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $52.34 |
52-Week Low | $29.84 | $41.33 |
Enterprise Value | $566.59M | $124.48B |
Dividend Yield | 2.47% | 5.56% |
Signals from Pluang's Aura AI — not financial advice
Build-A-Bear Workshop (BBW) trades at $36.86, up 6.19% today, with a bullish technical signal and strong analyst support. The stock exhibits attractive valuation metrics, including a P/E of 8.73 and P/S of 0.92, alongside robust profitability with a 10.48% net income margin and 35.87% ROE. Recent earnings have consistently beaten estimates, and the company maintains a debt-free balance sheet while executing a growth strategy focused on international expansion and brand partnerships.
The outlook for BBW is positive, driven by earnings momentum and a consensus price target of $62.50 implying significant upside. Key risks include near-term consumer spending volatility and execution of expansion plans, but strong fundamentals and shareholder returns via dividends support a favorable risk-reward profile for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →